Ixico secures two clinical trial contracts alongside partner VirtualScopics
Ixico has won two contracts to deploy its products in unnamed pharmaceutical companies' clinical trials, alongside its partner VirtualScopics.
FTSE AIM All-Share
750.49
08:20 23/04/24
Ixico
8.75p
16:55 22/04/24
Pharmaceuticals & Biotechnology
21,971.01
08:19 23/04/24
Both studies will employ Ixico's TrialTracker digital platform to collect and image data, one pertaining to metastatic solid tumours and the other to rare neurodegenerative diseases.
Ixico's Assessa technology will all be used to process MRI results.
The first study is expected to complete in June 2017, and the second in January 2018.
"Our alliance with VirtualScopics continues to be valued by our pharmaceutical partners as we support their clinical trials on a global basis, as evidenced by these two new contract wins," said chief executive officer Derek Hill, in a statement.
Shares in Ixico were untraded on Monday morning, but closed at 21p on Friday.